Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

This study tests a new CAR-T cell therapy that targets two proteins at once — CD19 and CD20 — on cancer cells in patients with B-cell lymphoma or leukemia that has come back or stopped responding to other treatments. **You may be eligible if...** - You have been diagnosed with relapsed or refractory B-cell lymphoma or B-cell acute lymphoblastic leukemia - Your cancer expresses CD19, CD20, or both proteins - You have received at least two prior lines of treatment - You are at least 18 years old with adequate organ function **You may NOT be eligible if...** - You have active brain involvement from your lymphoma - You have serious active infections (including untreated HIV or hepatitis) - You have received prior CAR-T cell therapy targeting CD19 or CD20 recently - You are pregnant or breastfeeding - You have serious heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.